Table 5. Sensitivity and specificity of bed-side measures/indexes to identify sarcopenia1 and sarcopenic obesity2.
| Variables | Sex | Cutoff | Sensitivity, % (95%CI) | Specificity, % (95%CI) |
|---|---|---|---|---|
| Sarcopenia | ||||
| AFFM+HGS | Female | AFFM≤15.87 + HGS<16 | 84.6 (78.4; 90.9) | 99.1 (97.5; 100.0) |
| Male | AFFM≤21.43 + HGS<27 | 1.00 (1.00; 1.00) | 99.2 (97.7; 100.0) | |
| pFFM+HGS | Female | pFFM≤35.02 + HGS<16 | 84.6 (78.4; 90.9) | 99.1 (97.5; 100.0) |
| Male | pFFM≤46.42 + HGS<27 | 1.00 (1.00; 1.00) | 1.00 (1.00; 1.00) | |
| CC+HGS | Female | CC≤35.5 + HGS<16 | 84.6 (78.4; 90.9) | 99.1 (97.5; 100.0) |
| Male | CC≤37.0 + HGS<27 | 1.00 (1.00; 1.00) | 1.00 (1.00; 1.00) | |
| Sarcopenic Obesity | ||||
| FMIBCM+AFFM | Female | FMIBCM>12.58 + AFFM≤15.87 | 75.0 (67.5; 82.5) | 97.5 (94.8; 100.0) |
| Male | FMIBCM>8.82 + AFFM≤21.43 | 75.0 (67.7; 82.3) | 95.3 (91.8; 98.9) | |
| FMIBCM+pFFM | Female | FMIBCM>12.58 + pFFM≤35.02 | 75.0 (67.5; 82.5) | 97.5 (94.8; 100.0) |
| Male | FMIBCM>8.82 + pFFM≤46.42 | 75.0 (67.7; 82.3) | 96.8 (93.9; 99.8) | |
| FMIBCM+CC | Female | FMIBCM>12.58 + CC≤35.5 | 12.5 (6.8; 18.2) | 98.3 (96.1; 100.0) |
| Male | FMIBCM>8.82 + CC≤37.0 | 50.0 (41.6; 58.4) | 96.1 (92.8; 99.3) | |
| pFMI+AFFM | Female | pFMI>12.2 + AFFM≤15.87 | 62.5 (54.1; 70.8) | 98.3 (96.1; 100.0) |
| Male | pFMI>8.76 + AFFM≤21.43 | 62.5 (54.3; 70.7) | 96.0 (92.7; 99.3) | |
| pFMI+pFFM | Female | pFMI>12.2 + pFFM≤35.02 | 62.5 (54.1; 70.8) | 98.3 (96.1; 100.0) |
| Male | pFMI>8.76 + pFFM≤46.42 | 62.5 (54.3; 70.7) | 96.8 (93.9; 99.8) | |
| pFMI+CC | Female | pFMI>12.2 + CC≤35.5 | 12.5 (6.8; 18.2) | 98.3 (96.1; 100.0) |
| Male | pFMI>8.76 + CC≤37.0 | 50.0 (41.5; 58.5) | 96.8 (93.9; 99.8) | |
| WC/H+AFFM | Female | WC/H>0.66 + AFFM≤15.87 | 50.0 (41.4; 58.6) | 95.9 (92.4; 99.3) |
| Male | WC/H>0.60 + AFFM≤21.43 | 75.0 (67.7; 82.3) | 92.8 (85.0; 97.2) | |
| WC/H+pFFM | Female | WC/H>0.66 + pFFM≤35.02 | 50.0 (41.4; 58.6) | 95.9 (94.4; 99.3) |
| Male | WC/H>0.60 + pFFM≤46.42 | 75.0 (67.7; 82.3) | 93.6 (89.5; 97.8) | |
| WC/H+CC | Female | WC/H>0.66 + CC≤35.5 | 12.5 (6.8; 18.2) | 95.9 (92.4; 99.3) |
| Male | WC/H>0.60 + CC≤37.0 | 50.0 (41.5; 58.5) | 92.9 (88.5; 97.2) | |
1ALM by Dual energy X-ray absorptiometry analysis, with ALM<15kg for women and ALM <20kg for men [10].
2FMI by Dual energy X-ray absorptiometry analysis, with FMI>13kg/m2 for women and FMI>9kg/m2 for men [14]. AFFM, appendicular fat free mass; CC, calf circumference; FMIBCM, fat mass index body composition monitor; pFFM, predicted fat free mass; pFMI, predicted fat mass index; WC/H, waist circumference for height ratio. AFFM, FMIBCM, pFMI and pFFM measures by bioelectrical impedance. AFFM by Sergi equation [20], pFM and pFFM by Bellafronte equation [22] and FMBCM by bioelectrical impedance from body composition monitor (Fresenius Medical Care).